United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Pfizer (PFE) Right Now?

AstraZeneca

Eli Lilly

Leading vaccine makers like Eli Lilly and Co. NYSE: LLY, Pfizer Inc. NYSE: PFE, and AstraZeneca plc NASDAQ: AZN may have faded from the spotlight since the peak of the COVID-19 pandemic, but now there is reason to expect renewed interest. As investors look ahead to the second Trump administration, the incoming president's nomination of outspoken vaccine critic Robert F.

Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch

British American Tobacco

Enterprise Products Partners

LyondellBasell Industries

Altria

I'm seeking 6%-plus yielding blue-chip bargains for my family's portfolio, with a focus on long-term income growth and minimal volatility. My ZEUS Family portfolio strategy involves annual rebalancing and screening for undervalued, high-quality stocks with strong fundamentals and risk management. I'm considering five blue-chip alternatives to Enbridge, offering 7% yields, 6-7% annual dividend growth, and 13-14% long-term income growth.

5 Blue Chips Yielding Over 7% I'm Considering Buying, And So Should You

One stock that just can't seem to catch a break of late is Pfizer (PFE 0.23%). Even though it posted some decent earnings numbers, investors can't shake the fear that the business is facing daunting headwinds that could send its $145 billion valuation lower in the months and years ahead.

Is Pfizer Stock in Trouble?

A list of high-quality dividend-growth stocks trading near 52-week lows is evaluated based on historical and future fair values. Pfizer's financial health is concerning, with unsustainable dividend payout ratios and negative debt-to-equity ratios, but future projections suggest a potential recovery. Despite political risks and activist investor concerns, PFE's high initial dividend yield, solid ratings, and promising pipeline make it a potentially undervalued investment.

High-Quality Dividend Growth Stocks Near 52-Week Lows: Pfizer Is Fun

Nobody can predict the future, but it's not hard to imagine increasing pharmaceutical sales. In 2022, prescription drug spending in the U.S. climbed more than 8% to reach $406 billion.

Billionaires Are Buying Up Beaten-Down Pfizer Stock. Should You Follow Their Lead?

Kinder Morgan

AT&T

Maintaining dividend aristocrat status isn't easy, as it requires companies to pay out dividends consistently (and raise them each year) for 25 consecutive years, while maintaining a $3 billion market capitalization and be included in the S&P 500 index.

Current, Future and Former Dividend Aristocrats Yielding Over 4% to Buy in November 2024

AbbVie

Investors looking for a way to pump up their passive income streams want to turn their attention toward the pharmaceutical industry. From the end of 2022 through Nov. 22, the benchmark S&P 500 index rose by a stunning 55.5%, but many of its drug-selling components haven't participated in the rally.

2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income

Bristol-Myers

Johnson & Johnson

Key Points Donald Trump's victory is positive for the stock market.

One Sector Has Underperformed Massively: These 4 Blue-Chip Dividend Giants Are Huge 2025 Plays

BridgeBio Pharma Inc

On Friday, the FDA approved BridgeBio Pharma, Inc.'s BBIO Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization.

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market

American Tower

KeyCorp

Merck

Paramount Global

SBA Communications

Seagate Technology Holdings PLC

Vistra Energy

Nvidia reported third-quarter profit that doubled — putting it near the top of the S&P 500's growth. But look for profit growth elsewhere.

Nvidia's Profit Ruled Last Quarter — Now It's These 8 Stocks' Turn

Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends.

3 Dividend Stocks That Are Screaming Buys in November

Pfizer Inc. (NYSE:PFE ) Jefferies London Healthcare Conference November 20, 2024 4:00 AM ET Company Participants Dave Denton - CFO Andrew Baum - Chief Strategy and Innovation Officer, EVP Conference Call Participants Akash Tewari - Jefferies Akash Tewari Good to start. All right.

Pfizer Inc. (PFE) Jefferies London Healthcare Conference (Transcript)

Dominion Energy

Dow Inc

Verizon

Exxon Mobil

Key Points It's likely the Federal Reserve will lower interest rates by another 25 basis points in December.

Baby Boomers Hit the Passive Income Lottery With 5 Blue-Chip Dividend Stocks

Pfizer's stock appears undervalued with a high dividend yield of 6.8%, making it a potential long-term investment despite low growth expectations. The company reported strong Q3 results with 31.2% YoY revenue growth, driven by products like Paxlovid and Comirnaty. Despite high valuation multiples, a DCF analysis suggests Pfizer's intrinsic value is $37.56 with 3% growth, indicating potential undervaluation.

Pfizer: High Dividend And Low Price Might Still Offset The Expanding Risks

Novo Nordisk

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO). But which of these two stocks offers value investors a better bang for their buck right now?

PFE vs. NVO: Which Stock Is the Better Value Option?

Alibaba

Ingredion

Leidos Hld

Latam Airlines Group SA

Here are the five PEG-driven value stocks that fit our screening criteria - INGR, PFE, LDOS, LTM and BABA.

5 Best Value Stocks With Discounted PEG to Boost Your Portfolio Return

CVS Health

Patterson Companies

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 5% Dividend Yields

Following approval from the European Commission, PFE's Hympavzi becomes the first hemophilia medicine in the European Union to be administered via a pre-filled, auto-injector pen.

Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU

2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist

2 Dividend Stocks That Pay More Than 6% That Retirees Can Safely Buy and Hold for Years

Zai Lab Ltd.

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab (“Zai Lab”, NASDAQ: ZLAB; HKEX: 9688) and Pfizer (“Pfizer”, NYSE: PFE) announced today a strategic collaboration for the novel antibacterial drug XACDURO® (sulbactam-durlobactam) in mainland China. Pfizer's affiliated companies will be exclusively authorized to undertake and perform certain commercialization activities for XACDURO® in mainland China. Through this collaboration, Zai Lab will leverage the industry-leading commercialization inf.

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)

Adobe

Dollar General

Ryanair Hlds

Snap

These five laggards of this year have double-digit upside left for the rest of 2024. These are: ADBE, PFE, DG, SNAP, RYAAY.

5 Year-to-Date Laggards to Buy Amid Solid Near-Term Upside Potential

News for Pfizer Stock (PFE)